Ralph T. Doyle, Jr.

Executive Director, Clinical Development
Amarin Pharma, Inc.

Amarin Pharma Inc. (Ownership Interest includes stock, stock options, patent or other intellectual property, Employment)

Poster(s):

• (P160) BENEFITS OF ICOSAPENT ETHYL IN PATIENTS WITH PRIOR PERIPHERAL ARTERY DISEASE: REDUCE-IT PAD
  Thursday, October 27, 2022

  6:10 PM – 6:20 PM EDT

• (P168) REDUCTION IN ISCHEMIC EVENTS, INCLUDING CARDIOVASCULAR MORTALITY, WITH ICOSAPENT ETHYL IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION: REDUCE-IT PRIOR MI
  Thursday, October 27, 2022

  5:40 PM – 5:50 PM EDT